Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,774.00
(
-1.49%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.12
(
6.43%
)
Bitcoin
71,303.48
(
-3.57%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: 10nisman post# 65828

Thursday, 09/04/2008 12:09:52 PM

Thursday, September 04, 2008 12:09:52 PM

Post# of 257257
>IDIX (Reason for yesterday's advance??)<

That the 100mg dose of IDX899 works as monotherapy is excellent news for two reasons:

1. The lower the dose, the better the tolerability will be when IDX899 is added to a standard treatment backbone such as Truvada.

2. The reason mentioned by Genisi (#msg-31929218): a lower dose has a smaller footprint, which facilitates co-formulation into a single pill with Truvada.

--
Still, I don’t think today’s news re the 100mg dose is what drove the share price yesterday because the data reported today were fully expected, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now